Efficacy and Safety on the Use of Bisphosphonates in Paediatrics

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04012320

Acronym

Bisphosphonate

Enrollment

Registered

2019-07-09

Start date

2018-10-31

Completion date

2018-12-31

Last updated

2019-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Events, Bisphosphonate-Associated Osteonecrosis, Bone Fragile, Children

Brief summary

The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.

Interventions

OTHERNo intervention, observational study

No intervention, observational study

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 18 Years

Healthy volunteers

Inclusion criteria

* be under 18 years of age * have been treated by intravenous bisphosphonates for primary or secondary osteoporosis

Exclusion criteria

* be over 18 years of age

Design outcomes

Primary

Measure	Time frame	Description
fracture rates	2 years	(numbers)
bone mineral density	2 years	(Z-score)
pain frequency	2 years	(never, occasional, regular)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026